GL
REGN icon

Graypoint LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Graypoint LLC’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$1.09M Buy
2,070
+55
+3% +$30.7K 0.06% 196
2025
Q1 		$1.28M Sell
2,015
-93
-4% -$64K 0.08% 167
2024
Q4 		$1.5M Sell
2,108
-238
-10% -$200K 0.09% 142
2024
Q3 		$2.47M Buy
2,346
+76
+3% +$84.6K 0.16% 106
2024
Q2 		$2.39M Buy
2,270
+136
+6% +$132K 0.16% 102
2024
Q1 		$2.05M Buy
2,134
+42
+2% +$39.9K 0.15% 112
2023
Q4 		$1.84M Buy
2,092
+47
+2% +$38.7K 0.15% 115
2023
Q3 		$1.68M Sell
2,045
-150
-7% -$118K 0.16% 114
2023
Q2 		$1.58M Sell
2,195
-225
-9% -$173K 0.16% 103
2023
Q1 		$1.99M Buy
2,420
+1,426
+143% +$1.08M 0.22% 88
2022
Q4 		$717K Buy
994
+63
+7% +$46.5K 0.09% 154
2022
Q3 		$641K Buy
931
+58
+7% +$36.5K 0.08% 163
2022
Q2 		$516K Sell
873
-35
-4% -$22.8K 0.07% 173
2022
Q1 		$634K Buy
908
+76
+9% +$48.1K 0.06% 181
2021
Q4 		$525K Buy
832
+72
+9% +$44.3K 0.06% 192
2021
Q3 		$460K Buy
760
+7
+0.9% +$4.35K 0.06% 174
2021
Q2 		$421K Buy
753
+66
+10% +$33.4K 0.06% 176
2021
Q1 		$325K Buy
687
+22
+3% +$10.7K 0.05% 180
2020
Q4 		$321K Sell
665
-22
-3% -$11.9K 0.06% 168
2020
Q3 		$385K Buy
687
+25
+4% +$15.2K 0.07% 141
2020
Q2 		$413K Hold
662
– – 0.09% 118
2020
Q1 		$323K Buy
+662
New +$273K 0.09% 115

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Graypoint LLC's REGN Position: Q2 2025 in Review

Graypoint LLC increased its Regeneron Pharmaceuticals (REGN) stake by 2.7% in Q2 2025, buying an estimated $30.7K and bringing the position to 2,070 shares worth $1.09M. The position accounts for 0.06% of the portfolio, ranked #196.

Graypoint LLC first reported a position in REGN in Q1 2020 and has held it in 22 quarters since. The position peaked at $2.47M in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Graypoint LLC held 2,070 shares of Regeneron Pharmaceuticals worth $1.09M as of Q2 2025.
  • Graypoint LLC bought 55 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $30.7K.
  • Regeneron Pharmaceuticals made up 0.06% of Graypoint LLC's portfolio in Q2 2025, its #196 holding.
  • Graypoint LLC first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 22 quarters since.
  • Graypoint LLC's Regeneron Pharmaceuticals position peaked at $2.47M in Q3 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Graypoint LLC's 13F filing for Q2 2025, filed 15 Jul 2025.